ERBB2 and urinary bladder carcinoma: Recently, several large-scale promising genomic studies of bladder cancer showed bladder cancers can split into three pan-cancer subtypes, which is unlike other human malignancies [10], although TP53, ErbB2, phosphatidylinositol-3-OH kinase/AKT/mTOR pathways are the major genomic alternation in bladder cancer as other human malignancies [11].